We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BN:EURONEXT PARISDanone SA Analysis

Data as of 2026-05-20 - not real-time

$44.28

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Brookfield Corporation trades around $44.28, well below the analyst median target of $56, offering a potential upside of over 20% while the Fear & Greed Index sits at an extreme‑greed 89.18. Current valuation metrics show a trailing P/E of 86.8 versus an industry average of 16.5, flagging the stock as overvalued on historic earnings, yet a forward P/E of 7.5 suggests the market is pricing in a rapid earnings rebound. Technical signals are mixed: the 20‑day SMA (45.51) sits above the price, the MACD histogram is negative and the signal line is bearish, and the RSI at 46.5 indicates neutral momentum, pointing to short‑term pressure toward the $42.95 support. The stock’s beta of ~1.6 and 30‑day volatility of 35% underscore heightened market sensitivity, while volume trends are increasing, providing decent liquidity. Fundamentally, the company generates solid operating cash flow ($9.5bn) but free cash flow is negative and debt‑to‑equity exceeds 160%, raising questions about the long‑term sustainability of its 0.63% dividend (payout ratio ~49%). Analyst sentiment remains positive with a “buy” consensus and a median price target of $56, driven by growth exposure in renewable power, infrastructure and private‑equity assets.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram and signal line
  • Price below 20‑day SMA
  • Proximity to technical support at $42.95

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward P/E of 7.5 indicating earnings acceleration
  • Analyst consensus buy with median target $56
  • Potential upside of ~22% per upside/downside metric

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Diversified global asset base in growth sectors
  • High debt levels and negative free cash flow
  • Dividend sustainability concerns despite modest payout

Key Metrics & Analysis

Financial Health

Revenue Growth7.90%
Profit Margin1.69%
P/E Ratio86.8
ROE2.50%
ROA2.64%
Debt/Equity161.47
P/B Ratio2.3
Op. Cash Flow$9.5B
Free Cash Flow$-2218749952
Industry P/E16.5

Technical Analysis

TrendNeutral
RSI46.5
Support$42.95
Resistance$48.60
MA 20$45.51
MA 50$43.05
MA 200$44.88
MACDBearish
VolumeIncreasing
Fear & Greed Index89.18

Valuation

Target Price$54.40
Upside/Downside22.85%
GradeOvervalued
TypeGrowth
Dividend Yield0.63%

Risk Assessment

Beta1.62
Volatility35.25%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.